Macellum Issues Final Letter to Kohl’s Shareholders Summarizing its Case for Boardroom Change
Contends the Election of Macellum Nominees Is a Necessary Insurance Policy to Preserve and Maximize Shareholder Value
Over the past two years, Macellum has worked tirelessly to help improve the Board and unlock enhanced value for all of the Company’s stakeholders following more than two decades of stagnation. In 2021, we were able to add two highly qualified director designees,
With the Annual Meeting in just two days, we urge our fellow shareholders to reflect on the following before casting their final ballots:
We believe voting on Macellum’s WHITE proxy card for at least a subset of our nominees, including a shareholder representative, is the best insurance policy for shareholders, regardless of whether a sale occurs or not.
- If Kohl's is on its way to being sold for a fair price, that will be a great outcome for shareholders. Voting for Macellum’s nominees will not change that outcome of a sale. In fact, our nominees would likely serve at a handful of meetings to discuss and approve a transaction and then would be another set of eyes in the boardroom for shareholders to help ensure a transaction is successfully completed.
However, should the Board have a sudden change of heartdue to the reelection of incumbents and misconstrues those results as support for management’s standalone plan, you should want Macellum nominees in the boardroom. We fear, as does Morgan Stanley analysts, that the Company’s share price could tumble into the low to mid $40s, effectively destroying more than
$1.5 billionin value, if a sale is not achieved. The Company’s standalone plan was not only poorly received when released on March 7, 2022, as reflected with a 13% drop in the stock price on that same day, but also relies on something that has not occurred in 10 years at Kohl’s – sales growth.
It is especially concerning that the current Board appears to be using, based on management’s standalone plan, targets of
$75per share to $88per share to benchmark offers against. We struggle to see any scenario where the Company’s capital-intensive and risky plan, which projects declining EBIT and increasing capital expenditures, will result in anything close to recently reported offers, even 3-years from now.
Shareholders should be wary of the Company’s refusal to share its results for the first quarter of fiscal 2023, despite their claims of business momentum.
- Underperformance in the first quarter of 2023, after a weak fourth quarter in fiscal 2022, would be more validation of a strategy that is not working. Shareholders need to ask why they are being forced to vote at the Annual Meeting without this critical piece of information. Cynically, perhaps, we suspect that if results were positive, they would have been made public by now.
- If true, weak performance could result in lower take-private prices that may not meet with the Board’s already unrealistic expectations. In this case, shareholders should want objective, unbiased voices on the Board to ensure expectations are level set.
Despite all the Board has said about conducting a robust process, there are still reasons to skeptical.
- We believe that had we not embarked on this campaign, buyers would never have surfaced and if we had not kept up our public pressure, the Board would have ignored this strategic interest. With the pressure off, how can we trust this Board to act in the best interests of shareholders?
- Keep in mind that earlier this year, the Board abruptly rejected indications of interest from two credible and well-capitalized acquirers before apparently providing sufficient access to management, a robust data room and other information that could have informed upward adjustments to such offers. The Board subsequently implemented an onerous, two-tiered poison pill that could only serve to chill acquirers’ interest.
Despite credible reports swirling about several suitors who are interested in bidding close to or above
$70per share, why does the stock still trade at a substantial discount to reported offer prices?
- While the Board could have delayed the Annual Meeting until July under applicable law, it chose to hold this year’s meeting before disclosing the results of its process. This lack of transparency goes to the heart of why Macellum nominees should be added to the Board at this critical time.
Lastly, shareholders should know that there is no recourse after this vote.
Wisconsinlaw allows the Board great flexibility to consider the interests of an expanded constituency to reject an offer, even if an offer may be in the best interest of shareholders. It is also notable that we, as shareholders, have no ability to hold the Board accountable before the 2023 annual meeting if the Board does not act in the best interests of shareholders following this year’s Annual Meeting.
Macellum has been a shareholder of Kohl’s for multiple years. We do not want an outcome at this year’s Annual Meeting that may lead to a permanent impairment of value.
We strongly urge you to help protect all shareholders and stakeholders by voting on Macellum’s WHITEproxy card. In our view, the greatest risk we can take as shareholders is doubling down on the current Board and management team once again after the last 20+ years of stagnation at Kohl’s.
Thank you for your support.
VOTE THE WHITE PROXY CARD TO ELECT MACELLUM’S ALIGNED AND EXPERIENCED SLATE.
LEARN MORE ABOUT MACELLUM’S SLATE HERE: WWW.KEEPKOHLSACCOUNTABLE.COM/NOMINEES
CONTACT INFO@SARATOGAPROXY.COM WITH QUESTIONS ABOUT YOUR PROXY AND HOW TO VOTE.
1 Share price decline reflects the period beginning